Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic

Prudkin, Ludmila; Nuciforo, Paolo

doi:10.1007/s13402-014-0192-6

Cited by 8 publications

(2 citation statements)

References 95 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most of them cannot be applied to clinical practice due to a lack of high sensitivity or/and specificity, compromising its reproducibility and its successful clinical implementation [7]. In this context, the recruitment of subjects, as well as the selection and management of tissues, is critical in biomarker research [8, 9].…”

Section: Introductionmentioning

confidence: 99%

In search of an evidence-based strategy for quality assessment of human tissue samples: report of the tissue Biospecimen Research Working Group of the Spanish Biobank Network

et al. 2019

View full text Add to dashboard Cite

The purpose of the present work is to underline the importance of obtaining a standardized procedure to ensure and evaluate both clinical and research usability of human tissue samples. The study, which was carried out by the Biospecimen Science Working Group of the Spanish Biobank Network, is based on a general overview of the current situation about quality assurance in human tissue biospecimens. It was conducted an exhaustive review of the analytical techniques used to evaluate the quality of human tissue samples over the past 30 years, as well as their reference values if they were published, and classified them according to the biomolecules evaluated: (i) DNA, (ii) RNA, and (iii) soluble or/and fixed proteins for immunochemistry. More than 130 publications released between 1989 and 2019 were analysed, most of them reporting results focused on the analysis of tumour and biopsy samples. A quality assessment proposal with an algorithm has been developed for both frozen tissue samples and formalin-fixed paraffin-embedded (FFPE) samples, according to the expected quality of sample based on the available pre-analytical information and the experience of the participants in the Working Group. The high heterogeneity of human tissue samples and the wide number of pre-analytic factors associated to quality of samples makes it very difficult to harmonize the quality criteria. However, the proposed method to assess human tissue sample integrity and antigenicity will not only help to evaluate whether stored human tissue samples fit for the purpose of biomarker development, but will also allow to perform further studies, such as assessing the impact of different pre-analytical factors on very well characterized samples or evaluating the readjustment of tissue sample collection, processing and storing procedures. By ensuring the quality of the samples used on research, the reproducibility of scientific results will be guaranteed.

show abstract

Section: Introductionmentioning

confidence: 99%

In search of an evidence-based strategy for quality assessment of human tissue samples: report of the tissue Biospecimen Research Working Group of the Spanish Biobank Network

et al. 2019

View full text Add to dashboard Cite

show abstract

“… 1 , 2 However, it is unclear whether the positive effects outbalance the increased costs or even lead to an overall cost reduction. 3 …”

Section: Introductionmentioning

confidence: 99%

Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer

Szucs¹,

Szillat²,

Blozik³

2018

PGPM

View full text Add to dashboard Cite

Single-nucleotide polymorphisms (SNPs) can severely impact individual drug response and health outcomes in cancer patients. Genetic tests to screen for marker SNPs are available to adjust the drug dose of oncologicals to the patient’s needs. However, it is unclear whether the positive effects outbalance the increased costs or even lead to an overall cost reduction. This very pragmatic analysis used three frequently used oncologicals for the treatment of breast cancer to evaluate whether preemptive pharmacogenetic testing may have a cost-reducing impact on health care spending in the Swiss health care system. Our results indicate that oncopharmacogenetics might help to reduce health care costs (ie, by avoiding adverse drug effects) and to increase efficiency of drugs in oncologic patients.

show abstract

Personalized cancer medicine: next steps in the genomic era

Derks

Diosdado

2015

Cell Oncol.

View full text Add to dashboard Cite

Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic

Cited by 8 publications

References 95 publications

In search of an evidence-based strategy for quality assessment of human tissue samples: report of the tissue Biospecimen Research Working Group of the Spanish Biobank Network

In search of an evidence-based strategy for quality assessment of human tissue samples: report of the tissue Biospecimen Research Working Group of the Spanish Biobank Network

Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer

Personalized cancer medicine: next steps in the genomic era

Contact Info

Product

Resources

About